Thia St Martin

Bedford Research Foundation — United States

Medicine · Health Sciences

11h-index1.1kcitations63works0.02yr avg
OpenAlex↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Lung Cancer Treatments and Mutations(43), Radiopharmaceutical Chemistry and Applications(23), HER2/EGFR in Cancer Research(14), RNA modifications and cancer(11), Cancer, Hypoxia, and Metabolism(9)

Publications63 total

Hidden rAAV Breakpoints Detected Using Single-Molecule, Modified Base Sequencing
2023Open Access
Supplementary Figure 6 from Discovery of a Mutant-Selective Covalent Inhibitor of EGFR that Overcomes T790M-Mediated Resistance in NSCLC
2023Open Access
Supplementary Figure 9 from Discovery of a Mutant-Selective Covalent Inhibitor of EGFR that Overcomes T790M-Mediated Resistance in NSCLC
2023Open Access
Supplementary Tables 1 through 4 and Supplementary Figures 1 through 5 from <i>In Vitro</i> and <i>In Vivo</i> Characterization of Irreversible Mutant-Selective EGFR Inhibitors That Are Wild-Type Sparing
2023Open Access
Supplementary Table 3 from Discovery of a Mutant-Selective Covalent Inhibitor of EGFR that Overcomes T790M-Mediated Resistance in NSCLC
2023Open Access
Supplementary Table 2 from Discovery of a Mutant-Selective Covalent Inhibitor of EGFR that Overcomes T790M-Mediated Resistance in NSCLC
2023Open Access
Supplementary Figure 1 from Discovery of a Mutant-Selective Covalent Inhibitor of EGFR that Overcomes T790M-Mediated Resistance in NSCLC
2023Open Access
Supplementary Figure 5 from Discovery of a Mutant-Selective Covalent Inhibitor of EGFR that Overcomes T790M-Mediated Resistance in NSCLC
2023Open Access
Supplementary Figure 10 from Discovery of a Mutant-Selective Covalent Inhibitor of EGFR that Overcomes T790M-Mediated Resistance in NSCLC
2023Open Access
Supplementary Figure 3 from Discovery of a Mutant-Selective Covalent Inhibitor of EGFR that Overcomes T790M-Mediated Resistance in NSCLC
2023Open Access
Supplementary Figure 6 from Discovery of a Mutant-Selective Covalent Inhibitor of EGFR that Overcomes T790M-Mediated Resistance in NSCLC
2023Open Access
Supplementary Figure 8 from Discovery of a Mutant-Selective Covalent Inhibitor of EGFR that Overcomes T790M-Mediated Resistance in NSCLC
2023Open Access
Supplementary Figure 8 from Discovery of a Mutant-Selective Covalent Inhibitor of EGFR that Overcomes T790M-Mediated Resistance in NSCLC
2023Open Access
Supplementary Figure 2 from Discovery of a Mutant-Selective Covalent Inhibitor of EGFR that Overcomes T790M-Mediated Resistance in NSCLC
2023Open Access
Supplementary Figure 7 from Discovery of a Mutant-Selective Covalent Inhibitor of EGFR that Overcomes T790M-Mediated Resistance in NSCLC
2023Open Access
Supplementary Materials and Methods and Supplementary Figure Legends from <i>In Vitro</i> and <i>In Vivo</i> Characterization of Irreversible Mutant-Selective EGFR Inhibitors That Are Wild-Type Sparing
2023Open Access
Supplementary Figure 1 from Discovery of a Mutant-Selective Covalent Inhibitor of EGFR that Overcomes T790M-Mediated Resistance in NSCLC
2023Open Access
Supplementary Figure 2 from Discovery of a Mutant-Selective Covalent Inhibitor of EGFR that Overcomes T790M-Mediated Resistance in NSCLC
2023Open Access
Data from <i>In Vitro</i> and <i>In Vivo</i> Characterization of Irreversible Mutant-Selective EGFR Inhibitors That Are Wild-Type Sparing
2023Open Access
Supplementary Materials and Methods and Supplementary Figure Legends from <i>In Vitro</i> and <i>In Vivo</i> Characterization of Irreversible Mutant-Selective EGFR Inhibitors That Are Wild-Type Sparing
2023Open Access
page 1 of 4Next →

Frequent Co-authors

Mariana Nacht(46), Russell C. Petter(42), William Westlin(42), Juswinder Singh(38), Zhendong Zhu(35), Prasoon Chaturvedi(35), Matthew Labenski(34), Russell Karp(34), Deqiang Niu(33), Annette O. Walter(30), Robert Tjin Tham Sjin(30), Henry J. Haringsma(30), Mitch Raponi(30), Jeff Etter(28), Andrew D. Simmons(28), Thomas C. Harding(28), Aleksandr Dubrovskiy(27), Michael Sheets(26), Andrew J. Allen(26), Kevin Lin(24)